

UW Department of Pharmacy Faculty Meeting Agenda  
 February 28, 2022 | 9:00 to 11:00 am  
 Zoom | Conference URL: <https://washington.zoom.us/j/97532125121>  
 Meeting ID: 975 3212 5121 | Zoom Phone Number: +1 206 337 9723

Topic/ Business	Presenter	Approx. Time	Page
Welcome and Announcements	White	10 min	
Approval of Minutes (January 2022 meeting) [Vote Requested]	White	5 min	2
Comments from the Dean	Sullivan	15 min	
DOP Hiring Plan	White Sullivan	10 min	
Lori Martell Affiliate Assistant Professor - BRAMS Appointment [Vote Requested]	Stergachis	5 min	4
Course Change Application [Vote Requested] <ul style="list-style-type: none"> <li>HEOR 505 Managed Care Pharmacy: Principles and Practice</li> </ul>	Chan	5 min	11
Curriculum Committee Update	Hansen	5 min	
UW Senate Update	Bansal Carlson	5 min	
Student Conduct and Professionalism Discussion	White Odegard	20 min	
Open Forum	White	20 min	

January 24, 2022

# Department of Pharmacy Faculty Meeting

9:00 – 11:00am

Zoom

**Meeting called by:** H. Steve White

**Note taker:** Katherine Painter

**Attendees:** Abby Winter, Alvin Goo, Andy Stergachis, Anirban Basu, Brian Werth, Cathy Yeung, Connor Henry, Don Downing, Douglas Barthold, Douglas Black, James Lin, Jasmine Mangrum, Jen Danielson, Jennie Do, Jennifer Bacci, Jennifer Chang, Josh Carlson, Joshua Villarreal, Katherine Painter, Lauren Cirrincione, Leigh Ann Mike, Lingtak-Neander Chan, Louis Garrison, Marina Gano, Mary Hebert, Maya Kimura, Melissa Barker-Haliski, Patricia Hedtke, Peggy Odegard, Rachel Firebaugh, Ryan Hansen, Saveena Ahmed, Sharon Wu, Shelly Gray, Steve Fijalka, Steve White, Teddy Johnson, Terri O'Sullivan, Zachary Marcum

## Minutes

**Agenda item:** Welcome and Announcements **Presenter:** H. Steve White

### Discussion:

Steve White welcomed attendees to the fourth week of the Winter quarter. It was announced there would be a pending email from the President and Provost for an upcoming town hall. The Curriculum Committee also plans to send out an email providing follow up guidance from this town hall. The White Coat Ceremony has been postponed with the new date now set for May 20, 2022 from 6:00-7:00pm in Hogness Auditorium. The virtual mock accreditation site visit will occur on February 11, 2022; more information regarding the schedule is forthcoming. The faculty self-study is in the final stages of review. Once this is fully reviewed, it will be submitted to ACPE by February 15, 2022. Reminder that the official accreditation visit will be virtual and begin on March 29, 2022.

**Agenda item:** Approval of Minutes (December 2021)  
[Vote Requested] **Presenter:** H. Steve White

### Discussion:

Requested motion of December minutes:

- First: Don Downing
- Second: Doug Barthold

No questions or comments posed. Minutes for December meeting were unanimously approved, no objections or abstentions.

**Agenda item:** Progress Committee Update **Presenter:** Jen Danielson

### Discussion:

Coming up in February there will be revisions to the Progress Policy to learn about the new curriculum and help students navigate it. Discussed the need for, or interest in, capping the total years allowed for a student to complete their program (e.g., six or seven years). The DOP does not have an established policy for this issue. Discussed how contextual the conversation is around approaching a student who does not pass a Core course when it is a prerequisite in a series and they need to extend their time in the program by a year, even if they are able to take other elective courses in the meantime. Expressed concerns that these students may miss continuity of recent research content and how there may be a disconnect with trying to revisit a course a year (or years) later, resulting

in loss of knowledge.

---

**Agenda item:** Curriculum Committee **Presenter:** Ryan Hansen

**Discussion:**

Regarding the upcoming accreditation, Ryan Hanssen has been working with Curtis Jefferson to walk through questions that are most likely to be posed (e.g., vision and mission statement, curriculum planning, etc.). The Committee officially voted to adopt a Core Series Lead. The Series Lead is intended to manage continuous quality improvement processes. Discussed challenges and errors scheduling the Spring curriculum as there has been transition between in-person and online and the end of the Gold curriculum. Reminder to faculty that if they are not teaching a Spring quarter course to review the schedule to ensure their course is not listed. The new Health Science Education Building is due to open in May 2022. Once opened, this will change the class assignment algorithm, which may cause further disruption. Ryan noted that there will be an FAQ coming from the Curriculum Committee.

---

**Agenda item:** UW Senate Update **Presenter:** Josh Carlson

**Discussion:**

There will be a proposal regarding an adjustment of graduate school policy around satisfactory/unsatisfactory designations that can be done the final week of the quarter to align with changes made during the pandemic and along with undergraduate programs. New legislation has been approved allowing retired faculty and staff to formally be allowed on councils as opposed to ad hoc. From Olympia, the Governor's budget approved raises up to 3% at UW, but this is not binding. Long term care insurance is likely to be suspended until mid-2023; there is a bill that would retrospectively refund for the amount of time that was suspended. The UW Senate is continuing to review the dispute and grievance policy.

---

**Agenda item:** Graduate Program Review **Presenter:** Andy Stergachis

**Discussion:**

Two weeks ago from this meeting was the conclusion of the site visit for graduate program academic review, which typically occurs every 10 years. For the DOP, CHOICE Institute HEOR graduate programs were the primary focus of this review, though the assessment looked at the entire SOP. Chair of the review committee said we have a strong school and programs, that there were no major concerns, and provided constructive feedback. SOP will likely hear back from internal review in the Spring quarter about the final report and decision. Areas of feedback provided were high cost of living for students, insufficient tuition waivers, and increasing available resources for DEI programs.

---

**Agenda item:** Open Forum **Presenter:** H. Steve White

**Discussion:**

Reminder of the upcoming 5<sup>th</sup> Annual Plein Center Research Lecture on the new Alzheimer's drug set for March 3, 2022. UW Medicine is in the midst of residency interviews with matches starting mid-March. The plan is to recruit 1-2 residents in behavioral health within pharmacy. UW Medicine will open a new behavioral health facility on the NW campus in 2023. Pharmacy students met with state legislators over two days in which over 40 legislators were interviewed. At the last Senior Leadership Committee, it was mentioned that 100 students had already been accepted into the 2026 graduating PharmD class and interviews were still ongoing. Staffing update is that Mark Ondrake is staying part-time to continue helping with fiscal responsibilities and Alyssa Camp is planning on returning from maternity leave end of March. Dr. White welcomed Dr. James Lin, who is teaching PHRMCY 516 and overseeing the integration of law content into the broader curriculum. Melissa Barker-Haliski noted that time schedules for her Spring quarter course have been released, so if anyone is interested in giving a Monday presentation, reach out to Melissa directly.

February 25, 2022

H. Steve White, PhD  
Chair, Department of Pharmacy  
School of Pharmacy, University of Washington

**Re: Recommendation of Lori Martell, PhD, as Affiliate Assistant Professor of Pharmacy**

I am pleased to support Dr. Lori Martell's appointment as Affiliate Assistant Professor of Pharmacy. With Karen Teal's relocation to the East Coast, the Biomedical Regulatory Affairs Program (BRAMS) is in *immediate* need of an instructional faculty member who can serve as a lead instructor for PHRMRA 550, "Advanced Technical Writing for Biomedical Regulatory Affairs", Spring quarter, 2022 (2 credits). Karen's recently announced departure leaves us with a big gap to fill with very little time between now and the beginning of Spring quarter, 2022. This is a critical, core courses for the BRAMS MS degree program.


Dr. Martell is keenly interested in and extremely well-qualified to teach this course. Dave Hammond and I have had excellent preliminary discussions with her and I would like to proceed with offering her the role of course-lead for PHRMRA 550. She is potentially going to also be requested to not only teaching this course in the future, but also Karen Teal's other core course, PHRMRA 546, "Technical Writing for Biomedical Regulatory Affairs," Winter quarters.

Lori earned her PhD in Pharmacology from the University of Michigan. She has a distinguished career as a medical/scientific writer. Her experience is impressive – some 20 years of experience in drug development (nonclinical through Phase IV) - - authoring and management of portfolio medical writing activities, including the clinical sections of global regulatory submissions. With respect to teaching, Lori provides guest lectures in several of our BRAMS courses, including the Skills and the Technical Writing courses. Her teaching evaluations are excellent. Earlier in her career she taught pharmacology for four years at Eastern Michigan University where she designed the instructional material and taught a course for 80-90 junior and senior students in their BS in Nursing Program. She also has an impressive list of publications & abstracts.

Based in Seattle, Lori presently holds the position Senior Director, Medical Writing, with [Lyell Immunopharma](#), Inc. Immediately prior, she held progressively responsible positions with Juno -> Celgene -> Bristol Myers Squibb leading to the role of Director, Global Scientific and Regulatory Documentation. There, she oversaw the Cell Therapy Medical and Technical Writing Group; managed Seattle-based Cell Therapy portfolio medical writing resourcing, budget and contracting; and authored and coordinated review processes for global clinical and regulatory documents to support corporate objectives and global regulatory submissions for CAR T-cell therapies.

In sum, Lori will be a valuable and timely addition to the BRAMS faculty and I fully support her affiliate faculty appointment. The entire BRAMS faculty team looks forward to working with Lori. Thank you very much for your consideration.

Sincerely,



Andy Stergachis, PhD, BPharm  
Professor of Pharmacy and Global Health  
Associate Dean, Graduate Programs & Research  
Interim Director, Biomedical Regulatory Affairs Program

**LORI A. MARTELL, PhD**

1620B Taylor Ave N Seattle, WA

Phone: 339-223-1373

e-mail: lorimartell5@gmail.com

---

**SUMMARY OF QUALIFICATIONS**

- Medical/scientific writer and clinical scientist with 19 years of experience in drug development (nonclinical through Phase IV), management of portfolio medical writing activities and the clinical sections of global regulatory submissions
  - Publication planning, pharmacogenomics, precision medicine, payer/reimbursement strategy, medical communications, pharmacology instructor

**PROFESSIONAL EXPERIENCE**

LYELL IMMUNOPHARMA, INC., South San Francisco, CA 10/2021 – present

**Senior Director, Medical Writing**

BRISTOL MYERS SQUIBB, Princeton, NJ (Seattle, WA/*CELGENE acquisition*) 11/2019 – 10/2021

**Director, Global Scientific and Regulatory Documentation**

CELGENE CORPORATION, Summit, NJ (Seattle, WA/*JUNO acquisition*) 01/2019 – 11/2019

**Director, Global Medical Writing and Submission Planning**

- Oversee Cell Therapy Medical and Technical Writing Group (n=4 internal, n=5 external contractors)
- Manage Seattle-based Cell Therapy portfolio medical writing resourcing, budget and contracting
- Strategic planning, authoring, coordinating review processes for global clinical and regulatory documents to support corporate objectives and global regulatory submissions for CAR T-cell therapies

JUNO THERAPEUTICS, INC., Seattle, WA

11/2016 – 12/2018

**Senior Director, Medical and Technical Writing**

- Strategic planning for Global Medical Writing activities across the Cell Therapy portfolio; established medical writing operating model
- Planning, authoring, coordinating review process for global clinical and regulatory documents to support strategic corporate objectives and clinical trials across the portfolio; documents included Clinical Protocols and Amendments, Investigator's Brochures, Clinical Study Reports, subject safety and efficacy narratives/summaries, Module 2 clinical summaries, regulatory documents
- Management of internal and external writers (n=4 internal, n=7 external), establishing process guidelines, quality standards, SOP development and company style guide; overall portfolio resourcing, budget and contracting oversight

ALEXION PHARMACEUTICALS, INC., Cambridge, MA

09/2013 – 11/2016

**Senior Director, Medical Writing**

- Strategic planning for Global Medical Writing activities across the portfolio; establishing medical writing line function
- Planning, authoring, coordinating review process for global clinical and regulatory documents to support strategic corporate objectives and submissions across the portfolio for Phase I-IV studies; documents include Clinical Protocols and Amendments, Investigator's Brochures, Clinical Study Reports, subject safety and efficacy narratives/summaries, Module 2 clinical summaries, regulatory briefing documents
  - Led clinical document submission/RFI along with Regulatory for STRENSIQ® (asfotase alfa) in EU, US, Japan, Canada, Australia and other regions
  - Authored Clinical Overview for SOLIRIS® (eculizumab) submission in generalized myasthenia gravis (US, EU)

- Management of internal and external writers (n=10 internal, n=10 external contractors), establishing process guidelines, quality standards, SOP development and company style guide; overall portfolio resourcing, budget and contracting oversight

ZIOPHARM ONCOLOGY, INC., Boston, MA

02/2012 – 8/2013

**Director, Clinical Science** (3/2013 – 8/2013)

**Director, Medical Writing** (2/2012 – 3/2013)

- Planning, authoring, coordinating review process for clinical and regulatory documents to support strategic corporate objectives and submissions across the portfolio for Phase I-III studies; documents included Clinical Protocols and Amendments, Investigator's Brochures, Clinical Study Reports, subject narratives, clinical summaries; target product profiles; communications team scientific messaging
- Strategic publication planning for small molecule and DNA Therapeutics programs; authoring abstracts, posters, manuscripts, presentations
- Clinical Advisory Board planning and Executive Summary preparation; NIH Recombinant DNA Advisory Committee (RAC) meeting preparation
- Management of internal and external writers, established quality standards and company style guide

GENERATION HEALTH / CVS CAREMARK, Waltham, MA

11/2009 – 2/2012

**Vice President, Clinical Products Research** (7/2011– 2/2012)

**Director, Clinical Content Strategy** (11/2009 – 7/2011)

- Strategic guidance and management over the clinical content development efforts within the Clinical Development team, architecture of genomic knowledgebase, authoring clinical utility evaluations and genetic test technology assessments, clinical decision support, medical policies
- Coordination and management of Clinical Advisory Board meetings
- Participation in business development efforts and product strategy
- Management of Research Analysts (4 direct reports)

METHYLGENE INC., Montréal, Québec

2006 – 2009

**Project Leader / Medical Writer**

- Lead of multidisciplinary Project Team for infectious disease program ( $\beta$ -lactamase inhibitor, fungal HOS2 inhibitor), translation of early nonclinical studies to IND to Phase I study design and Phase II strategy; alignment of project strategy and development goals for infectious disease and oncology molecules
- Author of core project documentation for HDAC inhibitor program, c-MET/VEGFR2 inhibitor,  $\beta$ -lactamase inhibitor; oral presentations for business development/licensing opportunities, coordination of Due Diligence, abstracts, manuscripts, Clinical Advisory Board Executive Summaries, nonclinical/clinical study reports

CURAGEN CORPORATION, Branford, Connecticut

2001 – 2006

**Contract Medical Writer**

- Writing and editing regulatory documents including nonclinical study reports, tabulated summaries, and other documents required for Investigational New Drug (IND) Applications, IND Annual Report, Investigator's Brochure

MARTELL MEDICAL COMMUNICATIONS, Guilford, CT and Montréal, Québec

2001 – 2008

**Founder**

- Authoring and editing medical content including Continuing Medical Education pieces, slide lecture materials for sales training and product dossier, marketing pieces, Advisory Board summary reports, symposia abstracts and KOL slide decks, white papers and manuscripts, product newsletters
- Therapeutic areas included oncology, neuropharmacology (Alzheimer's disease, migraine headache, schizophrenia, generalized anxiety disorder, depression), antibiotics, parenteral nutrition, vaccines (rotavirus, HPV) and antivirals (HIV)

*Contracts with:*

MEDPLAN COMMUNICATIONS INC, Montréal, Québec 1-yr contract  
Projects with **Pfizer, Inc., Merck-Frosst, and Shire PLC**

PHARMEDICA COMMUNICATIONS, LLC, Killingworth, Connecticut 5-yr extended contract  
Projects with **Pfizer, Inc., Bayer Pharmaceuticals, and Glaxo-Smith Kline**

SCIENCE VISION, LLC, Madison, Connecticut 3-yr extended contract  
Projects with **Bayer Pharmaceuticals and Oscient Pharmaceuticals**

MOSBY YEAR-BOOK, INC., St. Louis, Missouri 1990 – 2000  
**Reviewer/Editor** (contract position)

- Reviewing and editing medical textbooks and reference books such as *Physicians GenRx, Mosby's Nursing Drug Reference, Mosby's Pharmacology in Nursing, Mosby's Medical, Nursing, and Allied Health Dictionary, Pediatric Medications: A Handbook for Nurses, Pharmacology and the Nursing Process*

DUKE UNIVERSITY MEDICAL CENTER, Durham, North Carolina 1999 – 2000  
**Clinical Trial Coordinator**

- Site manager for a Phase III clinical trial - epoetin alfa (PROCRIT) in the elderly
- Prepared study overviews, consent forms for submission to local IRB and clinical research center, study plan and budget

UNIVERSITY OF MICHIGAN MEDICAL CENTER, Ann Arbor, Michigan 1991 – 1993  
Department of Surgery / Section of Neurosurgery  
**Research Investigator, Brain Tumor Laboratory**

- Brain tumor laboratory set-up in collaboration with neurosurgeons, lead primary researcher, grant writing
  - Novel immunotoxin therapy for brain tumors in adults and children using cell lines, primary cell cultures, and laboratory animals
  - Retinoic acid modulation of proliferation and differentiation in brain tumors

## TEACHING EXPERIENCE

UNIVERSITY OF WASHINGTON, Seattle, WA  
Biomedical Regulatory Affairs Master of Science (BRAMS) Program  
Department of Pharmacy  
**Guest Lecturer** 2020, 2021

EASTERN MICHIGAN UNIVERSITY, Ypsilanti, Michigan 1989 – 1992  
Department of Nursing Education  
**Pharmacology Instructor**

- Designed course for 80-90 junior and senior students in the Bachelor of Science in Nursing Program, created instructional materials including a course pack, handouts, quizzes, and exams

## EDUCATION

THE UNIVERSITY OF MICHIGAN MEDICAL SCHOOL Ann Arbor, Michigan  
PhD, Pharmacology, 1991  
Dissertation Research: *"The molecular interactions between the calcium-binding protein calmodulin, calmodulin-dependent enzyme systems and neurotransmitter receptors in bovine brain and neuroblastoma."*

INDIANA UNIVERSITY Bloomington, Indiana  
BS, Microbiology, 1985

## BIOMEDICAL RESEARCH EXPERIENCE

THE UNIVERSITY OF MICHIGAN, Ann Arbor, Michigan

1986-1991

**Researcher**, Doctoral Program, Pharmacology Department

- Doctoral Dissertation: explored the translocation of the endogenous Ca<sup>2+</sup>-binding protein calmodulin and calmodulin-dependent signaling in bovine brain and neuroblastoma cells
- Purified G proteins for reconstitution into phospholipid vesicles, and fusion with  $\alpha_2$ -adrenergic receptor-containing vesicles to reconstitute high affinity ligand binding
- Cytotoxic effects of the anti-leukemic drug ara-C and a derivative drug, 3'-amino deoxycytidine, on mouse and human leukemia cells using soft agar cloning techniques

INDIANA UNIVERSITY, Bloomington, Indiana

1983 – 1986

**Laboratory Assistant**, Pharmacology Department

- Researched the effects of genetic and streptozotocin-induced diabetes on rat hepatic biotransformation

Laboratory Assistant, Microbiology Department

- Characterized the growth and nutritional requirements of the novel photosynthetic bacterium *Rhodospseudomonas marina*, var. *agilis*

**Researcher**, Independent Research Project, Immunology Department

- Researched the role of elevated serum interferon- $\gamma$  levels in the molecular mechanisms of fever

## GRANTS AND FELLOWSHIPS

- Department of Surgery Grant, The University of Michigan, 1992-1994
- NIMH National Research Service Predoctoral Award, National Institutes of Mental Health, 1990-1991
- Rackham Predoctoral Fellowship, The University of Michigan, 1990-1991
- Rackham Dissertation Grant, The University of Michigan, 1989
- NIH Pharmacological Sciences Training Grant, The National Institutes of Health, 1987 –1988
- Regent's Fellowship, The University of Michigan, 1986-1987
- Bayard Floyd Microbiology Fellowship, Indiana University, 1985

## AWARDS AND HONORS

- Eli Lilly Travel Award, 1990
- Student Representative, Educational Programs Committee, Department of Pharmacology, The University of Michigan, 1988-1989

## PROFESSIONAL AFFILIATIONS

- American Medical Writers Association, 2001-Present
- Regulatory Affairs Professional Society, 2012 -Present



## PUBLICATIONS

### Peer-reviewed Articles

Desai NR, Canestaro WJ, Kyrychenko P, Chaplin D, **Martell LA**, Brennan T, Matlin O, and Choudhry NK. The impact of *CYP2C19* genetic testing on provider prescribing patterns for antiplatelet therapy following acute coronary syndromes and percutaneous coronary intervention. *Circ Cardiovasc Qual Outcomes*. 2013, Nov 6(6):694-9.

Canestaro WJ, Brooks DG, Chaplin D, Choudhry NK, Lawler E, **Martell LA**, Brennan T, and Wassman ER. Statin pharmacogenomics: opportunities to improve patient outcomes and healthcare costs with genetic testing. *J Pers Med* 2012, 2(4):158-174.

Canestaro WJ, **Martell LA**, Wassman EW, and Schatzberg RS. Health care payers: a gate or translational bridge to personalized medicine? *Personalized Med* 2012 Jan; 9(1):73-84.

Pfaller MA, Messer SA, Georgopapadakou N, **Martell LA**, Besterman JM, and Diekema DJ. Combination testing of MGCD290, a Hos2 histone deacetylase inhibitor, with azole antifungals against opportunistic fungal pathogens. *J Clin Microbiol* 2009 Dec;47(12):3797-804.

**Martell LA** and Muraszko KM. The potential role of immunoconjugates in targeting cytotoxic agents to brain tumors. *CNS Drugs* 1994;2(3):175-183.

**Martell LA**, Agrawal A, Ross DA, and Muraszko KM. Efficacy of transferrin receptor-targeted immunotoxins on pediatric brain tumors. *Cancer Res* 1993;53:1348-1353.

**Mangels LA** and Gnegy ME. Carbachol stimulates binding of a photoreactive calmodulin derivative to calmodulin-binding proteins in intact SK-N-SH human neuroblastoma cells. *J Biol Chem* 1992;267:5847-5854.

**Mangels LA**, Neubig RR, Hamm HE, and Gnegy ME. Calmodulin-binding distinguishes between  $\beta\gamma$  subunits of activated Go/Gi and transducin. *Biochemical J* 1992;283:683-690.

**Mangels LA** and Gnegy ME. Cyclic AMP accumulation alters calmodulin localization in SK-N-SH human neuroblastoma cells. *Mol Brain Res* 1992;12:103-110.

**Mangels LA** and Gnegy ME. Muscarinic receptor-mediated translocation of calmodulin in SK-N-SH human neuroblastoma cells. *Mol Pharmacol* 1990;37:820-826.

Watkins JB and **Mangels LA**. Hepatic biotransformation in lean and obese Wistar Kyoto rats: comparison to that in streptozotocin-pretreated Sprague-Dawley rats. *Comp Biochem Physiol* 1987;88C:159-164.

**Mangels LA**, Favinger JL, Madigan MT, and Gest H. Isolation and characterization of the N<sub>2</sub>-fixing marine photosynthetic bacterium *Rhodospseudomonas marina*, variety *agilis*. *FEMS Microbiol Lett* 1986;36:99-104.

### Invited Articles

**Martell LA** and Senich BA. Pharmacogenomics & Personalized Medicine: new ways to optimize drug therapy. *Specialty Pharmacy Times* Cover Article, March 2011 (published online).

<http://www.pharmacytimes.com/publications/specialty-pt/2011/February-2011/SPT-Feat-0211>

## Abstracts

Linette GP, Hamid O, Whitman ED, Nemunaitis JJ, Chesney J, Agarwala SS, Starodub A, Barrett JA., Marsh A, **Martell LA**, Cho A, Reed TD, Youssoufian H, Vergara-Silva A. "A Phase I open-label study of Ad-RTS-hIL-12, an adenovirus vector engineered to express hIL-12, under the control of an oral activator ligand in subjects with unresectable Stage III/IV melanoma" American Society for Clinical Oncology Annual Meeting, 2013.

Vergara-Silva A, Barrett J, Marsh A, Khosravi-Far R, **Martell LA**, Hamid O, Chan T, Reed TD, Youssoufian H, Nemunaitis J. "Delivery of IL-12 Shows Promising Clinical Activity in Unresectable Stage III/IV Melanoma" American Society of Gene & Cell Therapy Annual Meeting, 2013.

**Martell LA**, Reid GK, Martell R, Drouin M, Wilhelm J and Besterman JM. "Multiple Phase I Studies in Healthy Subjects Demonstrate Safety and Pharmacokinetics of MGCD290, an Oral Fungal Hos2 Inhibitor ± Fluconazole" ICAAC Annual Meeting, 2009.

**Martell LA**, Rahil G, Vaisburg A, Young K, Hickey E, Hermes J, Dinnino F, Besterman JM. "A Novel Beta-Lactamase Inhibitor Potentiates and Extends the Antibacterial Activity of Imipenem against  $\beta$ -Lactam-resistant *P. aeruginosa* and *K. pneumoniae*" ICAAC Annual Meeting, 2009.

Nguyen DT, Li J, Akache B, Hu W, **Martell LA**, Georgopapadakou N, Besterman JM. "MGCD290, a Novel Small Molecule, Modulates Azole Antifungal Activity through Specific Inhibition of the Histone Deacetylase HOS2" ICAAC Annual Meeting, 2009.

Conn KL, Traquir JA, MacGregor T, Nguyen DT, **Martell L**, Petropoulos L, Besterman JM. "A New Compound Class Synergizes with Fungicides to Inhibit Plant Pathogenic Fungi," American Phytopathological Society 2009.

Nguyen, DT, AkacheB, Ste-Croix H, Wang J, Ajamian A, Yeung B, Faltus R, Déziel R, **Martell L**, Besterman JM. "In vivo properties of MGCD290, an antifungal Hos2 histone deacetylase (HDAC) enzyme inhibitor" ICAAC/IDSA Annual Meeting, October 2008.

Muraszko KM, Cardneau J, **Martell L**, Lara G, Patel C, Youle R. "In Vitro Efficacy of Immunotoxins in Primary Pediatric Brain Tumors," American Society of Pediatric Neurosurgery, January, 1994.

**Martell LA** and Muraszko KM. "Platelet-derived Growth Factor Expression and Mitogenesis in Medulloblastoma Cells," Society for Neuroscience Meeting, 1993.

Agrawal A, **Martell LA**, Ross DA, and Muraszko, KM. "Retinoic Acid Modulation of Proliferation and Differentiation in Brain Tumors," Cancer Research, AACR, 1993.

**Martell LA**, Muraszko KM, Agrawal A, and Ross DA. "Efficacy of Transferrin Receptor-targeted Immunotoxins in Brain Tumors," Cancer Research, AACR, 1993.

**Mangels LA** and Gnegy ME. "Carbachol Stimulates Binding of a Photoreactive Calmodulin Derivative in SK-N-SH Human Neuroblastoma Cells," FASEB J, 5, A1233, 1991.

**Mangels LA** and Gnegy ME. "Adenylate Cyclase-coupled Activities Affect Muscarinic Receptor-mediated Calmodulin Translocation in SK-N-SH Human Neuroblastoma Cells," FASEB J, 4, A621, 1990.

**Mangels, L.A.** and Gnegy, M.E., "Muscarinic Receptor-Mediated Increase in Calmodulin Activity in SK-N-SH Human Neuroblastoma Cells," Soc Neurosci, Abstr. 15, 1005, 1989.

Elizondo R, Downing JF, **Mangels LA**, Wei KM, and Taylor MW. "Hyperthermia Augments Human Gamma-interferon Production by Two Possibly Distinct Mechanisms," Proc. of the Annual Meeting of the American Physiological Society, 1985.

Downing JF, **Mangels LA**, Martinez-Valdez H, and Taylor M. "Febrile Temperature Augments the Production of Gamma Interferon in Human Leukocyte Cultures," Proc. of the Annual Meeting of the American Physiology Society, 1985.

# COURSE CHANGE PROPOSAL

## Template

Only fill in **Required** items & **Items that will be changed**

### Course Information

Prefix ( <b>Required</b> )*	HEOR
Course Number ( <b>Required</b> )* Must be 3 digits Max <b>3 characters</b>	505
Department	
College/School	
Campus	
Course Title ( <b>Required</b> )* Do not use "&" symbol in the course title. Please spell out the word ("&" is OK for the abbreviated title). Max <b>120 characters</b>	Managed Care Pharmacy: Principles and Practice
Abbreviated Title ( <b>Required</b> )* Must be ALL CAPS Max <b>20 characters</b>	MANAGED CARE
First Effective Quarter/Year ( <b>Required</b> )*	Fall 2022
Last Effective Quarter/Year	
Course Description This description will appear in the course catalog. Max <b>450 characters</b>	
Recommended Preparation Course(s) or subject areas recommended to students prior to taking this course. Max <b>250 characters</b>	
Course Prerequisites Prerequisites as they will appear in the course catalog. Max <b>300 characters</b>	

#### Prerequisite Changes

This request is for a prerequisite change only which does not involve any other department's courses.

Enforce cancellation of registration if prerequisites not met (for undergraduate courses only)

#### Elective Lists

Add course to the following approved major/minor/option elective lists. Max **255 characters**

## Course Change Proposal – Template

--

### Anticipated Student Type

<input type="checkbox"/>	Undergraduate Majors/Minors
<input type="checkbox"/>	Undergraduate Non-Majors
<input type="checkbox"/>	Non-Matriculated Students
<input type="checkbox"/>	Graduate Students
<input type="checkbox"/>	Professional Students

### Anticipated Enrollment

25
----

## Proposal Information

This proposal is accompanied by one or more related add, drop or change proposals that need to be processed together.

### Justification (**Required**)\*

Explain why this course change is being proposed including its relationship to your overall curriculum. Is this course part of a broader curricular initiative? If so, please explain.

Course credits are being decreased from 3 to 2 to facilitate teaching by volunteer faculty and enable PharmD students to take the class alongside required courses. The class will meet 2 hrs/week at 1 session (previously was 3 hrs/wk over 2 sessions). We will remove the class project, which used to take up 1 hour per week in class contact time to allow the coursemasters to guide the students.
--

### Administrative Contact Information (**Required**)\*

Add the name of the department administrative contact who should be contacted in the case of any questions with this proposal. Start by typing in the contact's last name and select from the list of suggestions. Be sure to "Share" the proposal with this person as well so they will have access to edit the proposal prior to submission.

Patricia C. Hedtke <a href="mailto:pchedtke@uw.edu">pchedtke@uw.edu</a>
---

### Author(s)

Indicate the names of the people who participated in authoring this course proposal. (Optional)

--

## Credits

Credits (number)

<input type="checkbox"/>	2	Fixed	
<input type="checkbox"/>		Multiple	
<input type="checkbox"/>		Range	

## Course Change Proposal – Template

Multiple, Range or 0 Credit Comment

If multiple, range, or 0 credit, how will the number of credits be related to the amount of student effort?

Repeatable Credit

Course is Repeatable for Credit

## Activities and Hours

In-classroom Instructional and Additional Hours (**Required**)\*

One credit represents an approximate time commitment of 3 hours per week.

	Hours/Week
Lecture	2
Quiz Section	
Seminar	
Laboratory	
Studio	
Other	
Non-instructional Hours	4
TOTAL	6

Explanation and Justification for **"Other"** Instructional Hours

## Evaluation Details

Evaluation Details (**Required**) – must match what is in Syllabus

How will students be evaluated for credit or grades? **Provide specific information on assignments, projects, exams, etc. and relative % for each area.** Max **1000 characters**

Two Midterms: 40% (20% each)  
Final exam: 40%  
Participation in class: 20%

## Distance Learning

**Seattle Campus:** A course or sections of a course in which students can participate fully without being physically present on campus must be designated as a “DL” course or section. Attach a syllabus for the DL course as well as the in-classroom syllabus, if both are planned. See FCAS website for specific “DL” designation criteria: <https://www.washington.edu/cms/faculty/files/2014/05/DL-guideline.pdf>

**Bothell/Tacoma Campuses:** See Campus Curriculum Committees on guidelines for DL review/approval. This is a proposal to add Distance Learning designation to the course.

This is a proposal to renew Distance Learning designation (3 year review).

## Grading System

Grading (Required)\*

X	Standard or Credit/No Credit grading
	Credit/No credit grading only

Sequenced (Hyphenated) Courses

A sequenced (hyphenated) course is one in which the same course, or a series of courses, do not receive a final grade until the series has been completed. Please indicate position in sequence.

	of	
--	----	--

Prior course in the sequence is

--

## Scheduling

Quarters Offered

X	Autumn
	Winter
	Spring
	Summer

Odd or Even Years

	Only even years
	Only odd years
	Not specified

Instructor Name

Enter UW instructors if you would like their name to appear in the catalog. Start by typing in the instructors last name and select from the list of suggestions.

--

## Learning Objectives

Learning Objectives (Required)

By the end of this course, students will demonstrate the ability to: Max **2000 characters**

<ul style="list-style-type: none"><li>• Describe the organization of managed care pharmacy, and the approaches used to provide clinically sound, cost-effective pharmaceutical care.</li><li>• Identify the roles of managed care pharmacists in managing drug benefits for large patient populations</li><li>• Compare and contrast the different approaches for health technology assessment.</li><li>• Critically evaluate clinical and economic studies to inform drug monographs</li></ul>
---

## Curricular Relationship

List all curricular relationships associated with this course application. It is the responsibility of the initiating unit to do a good-faith review of existing courses to identify affected units. This application will

## Course Change Proposal – Template

automatically route to the identified units for review and comment. Failure to identify the affected departments here will delay action on this application.

### Offered Jointly With

Same course from two or more units. All courses within a joint loop satisfy prerequisite and program requirements.

Abbreviation	Number

### Jointly Offered Course Departments

For each course listed under Offered Jointly With, enter the related department here. Start by typing in the department name and select from the list of suggestions.

### Overlapping Courses

Significant content overlap of existing courses within or between UW campuses. Students only receive credit for one course. Does not necessarily satisfy prerequisite and program requirements for units involved.

### Overlapping Course Departments

For each course listed under Overlapping Courses, enter the related department here. Start by typing in the department name and select from the list of suggestions.

## Course Change Proposal – Template

### Equivalent Courses

Same course across two or more UW campuses. Courses satisfy prerequisite and program requirements for all units involved.

### Equivalent Course Departments

For each course listed under Equivalent Courses, enter the related department here. Start by typing in the department name and select from the list of suggestions.

### Potentially Affected Colleges, Schools, or Departments

Similar course content covered in one or more potentially affected units within or between UW campuses. Start by typing in the department name and select from the list of suggestions.

## Supporting Documents

### File/Description

Attach a **course syllabus/outline** (topic schedule) and reading list if this course will be offered for more than one quarter. If you are submitting a syllabus, please ensure it is compliant with FCAS Syllabus Guidelines and attendance is not listed as an evaluation type.